PMID- 36946241
OWN - NLM
STAT- MEDLINE
DCOM- 20230519
LR  - 20230526
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 10
IP  - 3
DP  - 2023 Jun
TI  - Health-related quality of life among transthyretin amyloid cardiomyopathy 
      patients.
PG  - 1871-1882
LID - 10.1002/ehf2.14350 [doi]
AB  - AIMS: Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe 
      heart disease with physical and psychological implications. The Nordic PROACT 
      study was conducted to investigate the health-related quality of life (HRQoL) in 
      ATTR CM patients. METHODS AND RESULTS: The Nordic PROACT study was a 
      cross-sectional non-interventional study conducted in 12 cardiology hospital 
      clinics across Norway, Sweden, Finland and Denmark. Men and women aged >/=18 years 
      diagnosed with symptomatic ATTR CM were included. The investigator provided 
      information on medical history, biomarkers, current treatment, co-morbidities and 
      disease severity according to the New York Heart Association (NYHA) class and the 
      National Amyloidosis Centre (NAC) staging. Patients completed the HRQoL 
      questionnaires in the form of the Kansas City Cardiomyopathy Questionnaire 
      (KCCQ), the EQ-5D-5L index with Visual Analog Scale (VAS), and the Major 
      Depression Inventory (MDI). A total of 169 patients (mean +/- SD age 
      77.7 +/- 6.2 years) were included. Ninety-two per cent were men. Seventy-six per 
      cent had wildtype ATTR CM (ATTRwt CM) and 15% had a hereditary form of ATTR CM 
      (ATTRv CM) while 9% were genetically unclassified. Most patients were in NYHA 
      class II (54%) and NAC stage 1 (53%). Participation in randomized clinical trials 
      (RCT) was noted in 58% of the patients. The 169 ATTR CM patients had a mean +/- SD 
      KCCQ score of 64.3 +/- 23.1 for total symptom score, 64.8 +/- 20.9 for overall 
      summary score (OSS) and 65.1 +/- 21.5 for clinical summary score. The EQ-5D-5L 
      total utility score was 0.8 +/- 0.2 and the EQ-5D-5L VAS score was 62.9 +/- 20.6. The 
      vast majority (89%) did not report any signs of depression. Patients with ATTRv 
      CM had a higher KCCQ OSS as compared with ATTRwt CM, while EQ-5D-5L utility 
      score, EQ-5D-5L VAS and MDI were similar. Non-RCT participants had a poorer HRQoL 
      as compared with RCT participants as reflected in lower KCCQ OSS and EQ-5D-5L VAS 
      scores and a higher MDI score. Patients with higher NYHA classes and NAC disease 
      stages had a poorer HRQoL as demonstrated by lower KCCQ and EQ-5D-5L scores and 
      higher MDI scores. Correlation between KCCQ, EQ-5D-5L and MDI and the covariate 
      NYHA class remained significant (P < 0.05) after adjusting for multiple testing. 
      CONCLUSIONS: KCCQ scores were lower than previously reported for patients with 
      other heart diseases of non-ATTR CM origin. The HRQoL measures correlated well to 
      NYHA class and NAC disease stage. The prevalence of depression appeared to be 
      low.
CI  - (c) 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of European Society of Cardiology.
FAU - Eldhagen, Per
AU  - Eldhagen P
AD  - Department of Medicine, Karolinska Institute, Karolinska University Hospital, 
      Solna, Sweden.
FAU - Lehtonen, Jukka
AU  - Lehtonen J
AD  - Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
FAU - Gude, Einar
AU  - Gude E
AD  - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
FAU - Gustafsson, Finn
AU  - Gustafsson F
AD  - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
FAU - Bagger-Bahnsen, Anne
AU  - Bagger-Bahnsen A
AD  - Pfizer Denmark, Ballerup, Denmark.
FAU - Vakevainen, Merja
AU  - Vakevainen M
AD  - Pfizer Finland, Helsinki, Finland.
FAU - Pilgaard, Trine
AU  - Pilgaard T
AD  - Pfizer Denmark, Ballerup, Denmark.
FAU - Wedell-Wedellsborg, Dorte
AU  - Wedell-Wedellsborg D
AD  - WW Projects, Copenhagen, Denmark.
FAU - Poulsen, Steen Hvitfeldt
AU  - Poulsen SH
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
CN  - Nordic PROACT study group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230322
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
RN  - 0 (Prealbumin)
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Prealbumin
MH  - Quality of Life/psychology
MH  - Surveys and Questionnaires
MH  - *Heart Diseases
MH  - *Cardiomyopathies
PMC - PMC10192258
OTO - NOTNLM
OT  - ATTR CM
OT  - Amyloidosis
OT  - Cardiomyopathy
OT  - Observational study
OT  - Patient-reported outcome measures
OT  - Quality of life
OT  - Transthyretin
COIS- J.L., E.G., and S.H.P. were paid by Pfizer for their work as members of the study 
      steering committee and were paid by Pfizer for their work as investigators in the 
      study. E.B., M.O., G.S., J.K., T.R., and E.C. were paid by Pfizer for their work 
      as investigators in the study. F.G. and P.E. are consultants for Pfizer. D.W.W. 
      was a paid contractor to Pfizer for her work as the CRO project leader role of 
      the study. A.B.B., M.V., T.P., K.J., M.K., and L.L.N. are full-time employees of 
      Pfizer. The authors report no other competing interests in this work.
EDAT- 2023/03/23 06:00
MHDA- 2023/05/19 06:42
PMCR- 2023/03/22
CRDT- 2023/03/22 05:43
PHST- 2023/02/22 00:00 [revised]
PHST- 2022/11/17 00:00 [received]
PHST- 2023/02/26 00:00 [accepted]
PHST- 2023/05/19 06:42 [medline]
PHST- 2023/03/23 06:00 [pubmed]
PHST- 2023/03/22 05:43 [entrez]
PHST- 2023/03/22 00:00 [pmc-release]
AID - EHF214350 [pii]
AID - 10.1002/ehf2.14350 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2023 Jun;10(3):1871-1882. doi: 10.1002/ehf2.14350. Epub 2023 Mar 
      22.